E
Aclaris Therapeutics, Inc.
ACRS
$1.19
$0.010.85%
E
Sell
11/22/2023Downgrade
Aclaris Therapeutics, Inc. (ACRS) was downgraded to E+ from D- on 11/22/2023 due to a decline in the total return index and volatility index.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to E+ from D- on 11/22/2023 due to a decline in the total return index and volatility index.
D
Sell
11/7/2023Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D- from E+ on 11/7/2023 due to an increase in the volatility index.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D- from E+ on 11/7/2023 due to an increase in the volatility index.
E
Sell
11/1/2023Downgrade
Aclaris Therapeutics, Inc. (ACRS) was downgraded to E+ from D- on 11/1/2023 due to a major decline in the solvency index, total return index and volatility index. The quick ratio declined from 9.39 to 5.27.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to E+ from D- on 11/1/2023 due to a major decline in the solvency index, total return index and volatility index. The quick ratio declined from 9.39 to 5.27.
D
Sell
3/14/2023Downgrade
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D- from D+ on 3/14/2023 due to a decline in the total return index and volatility index.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D- from D+ on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
3/8/2023Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D+ from D on 3/8/2023 due to an increase in the valuation index.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D+ from D on 3/8/2023 due to an increase in the valuation index.
D
Sell
2/23/2023Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
D
Sell
2/8/2023Downgrade
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
5/31/2022Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index and volatility index.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index and volatility index.
D
Sell
5/13/2022Downgrade
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D- from D on 5/13/2022 due to a decline in the total return index.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D- from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/5/2022Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and volatility index.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and volatility index.
D
Sell
4/20/2022Downgrade
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the growth index, total return index and valuation index. Operating cash flow declined 60.99% from -$10.61M to -$17.08M, total revenue declined 9.52% from $1.66M to $1.5M, and earnings per share declined from -$0.3454 to -$0.3724.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the growth index, total return index and valuation index. Operating cash flow declined 60.99% from -$10.61M to -$17.08M, total revenue declined 9.52% from $1.66M to $1.5M, and earnings per share declined from -$0.3454 to -$0.3724.
D
Sell
11/23/2021Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index and total return index.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index and total return index.
D
Sell
11/8/2021Downgrade
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index and growth index. EBIT declined 46.87% from -$13.21M to -$19.4M, total revenue declined 9.05% from $1.82M to $1.66M, and earnings per share declined from -$0.3365 to -$0.3454.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index and growth index. EBIT declined 46.87% from -$13.21M to -$19.4M, total revenue declined 9.05% from $1.82M to $1.66M, and earnings per share declined from -$0.3365 to -$0.3454.
D
Sell
5/8/2020Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D from D- on 5/8/2020 due to a major increase in the growth index, volatility index and valuation index. Operating cash flow increased 66.63% from -$20.39M to -$6.81M, total revenue increased 28.49% from $1.1M to $1.41M, and EBIT increased 21.58% from -$17.42M to -$13.66M.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D from D- on 5/8/2020 due to a major increase in the growth index, volatility index and valuation index. Operating cash flow increased 66.63% from -$20.39M to -$6.81M, total revenue increased 28.49% from $1.1M to $1.41M, and EBIT increased 21.58% from -$17.42M to -$13.66M.
D
Sell
3/29/2019Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D- from E+ on 3/29/2019 due to an increase in the growth index and efficiency index. Total revenue increased 125.37% from $1.63M to $3.67M, total capital increased 67.19% from $146.92M to $245.64M, and operating cash flow increased 8.74% from -$29.86M to -$27.25M.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D- from E+ on 3/29/2019 due to an increase in the growth index and efficiency index. Total revenue increased 125.37% from $1.63M to $3.67M, total capital increased 67.19% from $146.92M to $245.64M, and operating cash flow increased 8.74% from -$29.86M to -$27.25M.
E
Sell
2/4/2019Downgrade
Aclaris Therapeutics, Inc. (ACRS) was downgraded to E+ from D- on 2/4/2019 due to a substantial decline in the total return index, growth index and solvency index. Total revenue declined 55.71% from $3.68M to $1.63M, operating cash flow declined 36.76% from -$21.83M to -$29.86M, and the quick ratio declined from 8.31 to 6.07.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to E+ from D- on 2/4/2019 due to a substantial decline in the total return index, growth index and solvency index. Total revenue declined 55.71% from $3.68M to $1.63M, operating cash flow declined 36.76% from -$21.83M to -$29.86M, and the quick ratio declined from 8.31 to 6.07.
D
Sell
8/3/2018Downgrade
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D- from D on 8/3/2018 due to a major decline in the volatility index, total return index and efficiency index. Total capital declined 13.17% from $200.61M to $174.2M, and net income declined 3.27% from -$30.23M to -$31.22M.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D- from D on 8/3/2018 due to a major decline in the volatility index, total return index and efficiency index. Total capital declined 13.17% from $200.61M to $174.2M, and net income declined 3.27% from -$30.23M to -$31.22M.
D
Sell
5/12/2017Downgrade
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D from D+ on 5/12/2017 due to a major decline in the total return index, growth index and solvency index. Operating cash flow declined 56.83% from -$8.07M to -$12.66M, and EBIT declined 16.37% from -$11.11M to -$12.93M.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to D from D+ on 5/12/2017 due to a major decline in the total return index, growth index and solvency index. Operating cash flow declined 56.83% from -$8.07M to -$12.66M, and EBIT declined 16.37% from -$11.11M to -$12.93M.
D
Sell
5/1/2017Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D+ from D on 5/1/2017 due to an increase in the total return index, volatility index and efficiency index. Total capital increased 108.93% from $81.12M to $169.49M.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D+ from D on 5/1/2017 due to an increase in the total return index, volatility index and efficiency index. Total capital increased 108.93% from $81.12M to $169.49M.
D
Sell
1/3/2017Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D from D- on 1/3/2017 due to a large increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.6229 to -$0.4993, and EBIT increased 16.76% from -$12.99M to -$10.81M.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D from D- on 1/3/2017 due to a large increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.6229 to -$0.4993, and EBIT increased 16.76% from -$12.99M to -$10.81M.
D
Sell
7/1/2016Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D- from E on 7/1/2016 due to an increase in the valuation index and efficiency index.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to D- from E on 7/1/2016 due to an increase in the valuation index and efficiency index.
E
Sell
5/13/2016Downgrade
Aclaris Therapeutics, Inc. (ACRS) was downgraded to E from E+ on 5/13/2016 due to a decline in the efficiency index, growth index and solvency index. Net income declined 176.6% from -$4.71M to -$13.04M, earnings per share declined from -$0.2763 to -$0.6464, and EBIT declined 109.15% from -$4.51M to -$9.44M.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to E from E+ on 5/13/2016 due to a decline in the efficiency index, growth index and solvency index. Net income declined 176.6% from -$4.71M to -$13.04M, earnings per share declined from -$0.2763 to -$0.6464, and EBIT declined 109.15% from -$4.51M to -$9.44M.
E
Sell
5/12/2016Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to E+ from E on 5/12/2016 due to an increase in the valuation index.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to E+ from E on 5/12/2016 due to an increase in the valuation index.
E
Sell
4/19/2016Downgrade
Aclaris Therapeutics, Inc. (ACRS) was downgraded to E from E+ on 4/19/2016 due to a decline in the valuation index and volatility index.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to E from E+ on 4/19/2016 due to a decline in the valuation index and volatility index.
E
Sell
4/1/2016Upgraded
Aclaris Therapeutics, Inc. (ACRS) was upgraded to E+ from E on 4/1/2016 due to a significant increase in the total return index, solvency index and growth index. The quick ratio increased from 20.25 to 54.58, earnings per share increased from -$5.1121 to -$0.2763, and operating cash flow increased 60.85% from -$10.57M to -$4.14M.
Aclaris Therapeutics, Inc. (ACRS) was upgraded to E+ from E on 4/1/2016 due to a significant increase in the total return index, solvency index and growth index. The quick ratio increased from 20.25 to 54.58, earnings per share increased from -$5.1121 to -$0.2763, and operating cash flow increased 60.85% from -$10.57M to -$4.14M.
E
Sell
12/31/2015None
Aclaris Therapeutics, Inc. (ACRS) was downgraded to E from U on 12/31/2015.
Aclaris Therapeutics, Inc. (ACRS) was downgraded to E from U on 12/31/2015.
NASDAQ
05/17/2024 4:00PM Eastern
Quotes delayed
